{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:08:21Z","timestamp":1779451701437,"version":"3.53.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1182","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Basic Science Research Program"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009122","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2022R1C1C1005415"],"award-info":[{"award-number":["NRF-2022R1C1C1005415"]}],"id":[{"id":"10.13039\/100009122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study compared the efficacies of proton beam therapy (PBT) alone and PBT after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively studied 917 patients with HCC treated with PBT alone (PBT group, n\u2009=\u2009354) or PBT following TACE (TACE-PBT group, n\u2009=\u2009563) between 2016 and 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Before propensity score matching (PSM), there were no significant differences in local control (LC) or overall survival (OS). After PSM, there was no difference in OS between the 2 groups (P\u2009=\u2009.124), while LC showed a trend toward favoring TACE-PBT group (2-year LC: 97.4% vs. 94.8%, P\u2009=\u2009.068). In the subgroup of patients with mALBI grade 1 and absence of portal vein tumor thrombus, both LC and OS were significantly improved (P\u2009=\u2009.017 and P\u2009=\u2009.002, respectively). Moreover, there were no significant differences in mALBI grade distribution at 1, 3, and 6\u2009months post-treatment (P\u2009=\u2009.231, P\u2009=\u2009.158, and P\u2009=\u2009.683, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While adding TACE before PBT marginally improved LC, it did not confer any benefit in the OS. Given the excellent LC achieved with PBT alone, the modest absolute benefit of adding TACE should be carefully weighed against individual patient factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>This first large-scale study comparing PBT alone and TACE-PBT in HCC patients, demonstrating that PBT alone achieves excellent LC, with limited additional benefit from TACE except in selected subgroups. These findings help refine patient selection for combined therapy to maximize clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqag074","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:32:01Z","timestamp":1775759521000},"page":"1221-1231","source":"Crossref","is-referenced-by-count":0,"title":["Proton beam therapy with or without transarterial chemoembolization for hepatocellular carcinoma: a propensity score matching analysis"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-0394","authenticated-orcid":false,"given":"Jen-Yu","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology & Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Kaohsiung 83301,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul 06351,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-7263","authenticated-orcid":false,"given":"Jeong Il","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul 06351,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul 06351,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Ha","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul 06351,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Koo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul 06351,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongho","family":"Hyun","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ewha Womans University Medical Center , Seoul 07804,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Han","family":"Paik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul 06351,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2026052207305598900_tqag074-B1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fonc.2020.01205","article-title":"Long-term survival analysis of transarterial chemoembolization plus radiotherapy vs. radiotherapy for hepatocellular carcinoma with macroscopic vascular invasion","volume":"10","author":"Su","year":"2020","journal-title":"Front Oncol"},{"key":"2026052207305598900_tqag074-B2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ijrobp.2024.09.021","article-title":"External beam radiation therapy after transarterial chemoembolization versus transarterial chemoembolization alone for treatment of inoperable hepatocellular carcinoma: a randomized phase 3 trial","volume":"121","author":"Chen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052207305598900_tqag074-B3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026052207305598900_tqag074-B4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/jgh.12087","article-title":"Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma","volume":"28","author":"Honda","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"2026052207305598900_tqag074-B5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.21037\/hbsn-21-405","article-title":"The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021","volume":"12","author":"Cheung","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026052207305598900_tqag074-B6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3350\/cmh.2022.0294","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"28","author":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"2026052207305598900_tqag074-B7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jfma.2020.10.031","article-title":"Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan liver cancer association and the gastroenterological society of Taiwan","volume":"120","author":"Shao","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"2026052207305598900_tqag074-B8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.radonc.2015.11.019","article-title":"Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: an external validation study","volume":"118","author":"Yu","year":"2016","journal-title":"Radiother Oncol"},{"key":"2026052207305598900_tqag074-B9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ijrobp.2011.03.019","article-title":"Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes","volume":"82","author":"Yoon","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052207305598900_tqag074-B10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026052207305598900_tqag074-B11","doi-asserted-by":"publisher","first-page":"110223","DOI":"10.1016\/j.radonc.2024.110223","article-title":"Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma","volume":"194","author":"Liu","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026052207305598900_tqag074-B12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.semradonc.2017.04.002","article-title":"Radiation-induced liver toxicity","volume":"27","author":"Munoz-Schuffenegger","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"2026052207305598900_tqag074-B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1748-717X-8-48","article-title":"What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy","volume":"8","author":"Toramatsu","year":"2013","journal-title":"Radiat Oncol"},{"key":"2026052207305598900_tqag074-B14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.meddos.2007.04.008","article-title":"Proton radiotherapy for liver tumors: dosimetric advantages over photon plans","volume":"33","author":"Wang","year":"2008","journal-title":"Med Dosim"},{"key":"2026052207305598900_tqag074-B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","article-title":"Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival","volume":"105","author":"Sanford","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052207305598900_tqag074-B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13014-020-01605-4","article-title":"Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis","volume":"15","author":"Cheng","year":"2020","journal-title":"Radiat Oncol"},{"key":"2026052207305598900_tqag074-B17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijrobp.2023.09.047","article-title":"Proton beam therapy for hepatocellular carcinoma: multicenter prospective registry study in Japan","volume":"118","author":"Mizumoto","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052207305598900_tqag074-B18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijrobp.2021.03.049","article-title":"A phase 2 study of image-guided proton therapy for operable or ablation-treatable primary hepatocellular carcinoma","volume":"111","author":"Iwata","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052207305598900_tqag074-B19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fonc.2020.00542","article-title":"Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"2026052207305598900_tqag074-B20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026052207305598900_tqag074-B21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.radonc.2020.02.019","article-title":"Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma","volume":"146","author":"Yoo","year":"2020","journal-title":"Radiother Oncol"},{"key":"2026052207305598900_tqag074-B22","doi-asserted-by":"publisher","first-page":"109841","DOI":"10.1016\/j.radonc.2023.109841","article-title":"External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion","volume":"187","author":"Yu","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026052207305598900_tqag074-B23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/ph17081057","article-title":"Hypoxia as a target for combination with transarterial hemoembolization in hepatocellular carcinoma","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026052207305598900_tqag074-B24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3389\/fonc.2020.00562","article-title":"Tumor hypoxia: impact on radiation therapy and molecular pathways","volume":"10","author":"Sorensen","year":"2020","journal-title":"Front Oncol"},{"key":"2026052207305598900_tqag074-B25","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/cncr.34965","article-title":"Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial","volume":"129","author":"Bush","year":"2023","journal-title":"Cancer"},{"key":"2026052207305598900_tqag074-B26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO-24-01532","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: a randomized, open-label, controlled trial","volume":"43","author":"Xi","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026052207305598900_tqag074-B27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB (Oxford)"},{"key":"2026052207305598900_tqag074-B28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.radonc.2017.11.013","article-title":"Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review","volume":"129","author":"Rim","year":"2018","journal-title":"Radiother Oncol"},{"key":"2026052207305598900_tqag074-B29","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3350\/cmh.2023.0274","article-title":"Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2026052207305598900_tqag074-B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semcancer.2023.11.006","article-title":"Tumor hypoxia and radiotherapy: a major driver of resistance even for novel radiotherapy modalities","volume":"98","author":"Beckers","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"2026052207305598900_tqag074-B31","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.ijrobp.2010.10.007","article-title":"Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia","volume":"79","author":"Carlson","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026052207305598900_tqag074-B32","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s12072-022-10423-7","article-title":"Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial","volume":"16","author":"Guo","year":"2022","journal-title":"Hepatol Int"},{"key":"2026052207305598900_tqag074-B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/mco.2013.196","article-title":"Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"2","author":"Kang","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"2026052207305598900_tqag074-B34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3349\/ymj.2021.62.5.409","article-title":"Optimal timing of radiotherapy after incomplete transarterial chemoembolization for Barcelona clinic liver cancer stage B hepatocellular carcinoma","volume":"62","author":"Byun","year":"2021","journal-title":"Yonsei Med J"},{"key":"2026052207305598900_tqag074-B35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/1754-9485.13794","article-title":"Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma","volume":"69","author":"Song","year":"2025","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag074\/67937237\/tqag074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1182\/1221\/67937237\/tqag074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1182\/1221\/67937237\/tqag074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:31:13Z","timestamp":1779449473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1182\/1221\/8627009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":35,"journal-issue":{"issue":"1182","published-online":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag074","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,7]]}}}